[1] SOARES M O,WELTON N J,HARRISON D A,et al.An evaluation of the feasibility,cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock):incorporating a systematic review,meta-analysis and value of information analysis[J].Health Technol Assess,2012,16(7):1-186.
[2] MARIK P E.Surviving sepsis:going beyond the guidelines[J].Ann Intensive Care,2011,1(1):17.
[3] LEVY M M,FINK M P,MARSHALL J C,et al.SCCM/ESICM/ACCP/ATS/SIS:2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference[J].Crit Care Med,2003,31:1250-1256.
[4] O'BRIEN J M Jr,ALI N A,ABEREGG S K,et al.Sepsis[J].Am J Med,2007,120:1012-1022.
[5] VINCENT J L,RELLO J,MARSHALL J,et al.International study of the prevalence and outcomes of infection in intensive care units[J].JAMA,2009,302(21):2323-2329.
[6] DELLINGER R P,LEVY M M,CARLET J M,et al.Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock[J].Intens Care Med,2008,34:17-60.
[7] REMICK D G.Pathophysiology of sepsis[J].Am J Pathol,2007,170:1435-1444.
[8] MONNERET G,VENET F,PACHOT A,et al.Monitoring immune dysfunctions in the septic patient:a new skin for the old ceremony[J].Mol Med,2008,14(1-2):64-78.
[9] RIEDEMANN N C,GUO R F,WARD P A.The enigma of sepsis[J].J Clin Invest,2003,112:460-467.
[10] BAROCHIA A V,CUI X,VITBERG D,et al.Bundled care for septic shock:an analysis of clinical trials[J].Crit Care Med,2010,38:668-678.
[11] HOTCHKISS R S,SWANSON P E,FREEMAN B D,et al.Apoptotic cell death in patients with sepsis,shock,and multiple organ dysfunction[J].Crit Care Med,1999,27:1230-1251.
[12] HOTCHKISS R S,TINSLEY K W,SWANSON P E,et al.Sepsis-induced apoptosis causes progressive profound depletion of B and CD4T lymphocytes in humans[J].J Immunol,2001,166:6952-6963.
[13] HOTCHKISS R S,TINSLEY K W,SWANSON P E,et al.Depletion of dendritic cells,but not macrophages,in patients with sepsis[J].J Immunol,2002,168:2493-2500.
[14] LANDELLE C,LEPAPE A,VOIRIN N,et al.Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock[J].Intens Care Med,2010,36:1859-1866.
[15] HUANG X,VENET F,WANG Y L,et al.PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis[J].Proc Natl Acad Sci USA,2009,106:6303-6308.
[16] BRAHMAMDAM P,INOUE S,UNSINGER J,et al.Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis[J].J Leukoc Biol,2010,88:233-240.
[17] VENET F,CHUNG C S,MONNERET G,et al.Regulatory T cell populations in sepsis and trauma[J].J Leukoc Biol,2008,83:523-535.
[18] INOUE S,BO L,BIAN J,et al.Dose-dependent effect of anti-CTLA-4 on survival in sepsis[J].Shock,2011,36:38-44.
[19] DELANO M J,SCUMPIA P O,WEINSTEIN J S,et al.MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis[J].J Exp Med,2007,204(6):1463-1474.
[20] TORGERSEN C,MOSER P,LUCKNER G,et al.Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis[J].Anesth Analg,2009,108:1841-1847.
[21] KOLLEF K E,SCHRAMM G E,WILLS A R,et al.Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria[J].Chest,2008,134:281-287.
[22] LIMAYE A P,KIRBY K A,RUBENFELD G D,et al.Cytomegalovirus reactivation in critically ill immunocompetent patients[J].JAMA,2008,300:413-422.
[23] LUYT C E,COMBES A,DEBACK C,et al.Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation[J].Am J Respir Crit Care Med,2007,175:935-942.
[24] MEISEL C,SCHEFOLD J C,PSCHOWSKI R,et al.Granulocyte-macrophage colonystimulating factor to reverse sepsis-associated immunosuppression:a double-blind,randomized,placebo-controlled multicenter trial[J].Am J Respir Crit Care Med,2009,180:640-648.
[25] HALL M W,KNATZ N L,VETTERLY C,et al.Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome[J].Intens Care Med,2011,37:525-532.
[26] UNSINGER J,McGLYNN M,KASTEN K R,et al.IL-7 promotes T cell viability,trafficking,and functionality and improves survival in sepsis[J].J Immunol,2010,184:3768-3779.
[27] SPORTES C,HAKIM F T,MEMON S A,et al.Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets[J].J Exp Med,2008,205:1701-1714.
[28] LEVY Y,LACABARATZ C,WEISS L,et al.Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment[J].J Clin Invest,2009,119:997-1007.
[29] PATEL A,PATEL J,IKWUAGWU J.A case of progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia[J].J Antimicrob Chemother,2010,65:2697-2698.
[30] PELLEGRINI M,CALZASCIA T,TOE J G,at al.IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology[J].Cell,2011,144:601-613.
[31] MUELLER S N,VANGURI V K,HA S J,et al.PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice[J].J Clin Invest,2010,120:2508-2515.
[32] BRAHMER J R,DRAKE C G,WOLLNER I,et al.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:safety,clinical activity,pharmacodynamics,and immunologic correlates[J].J Clin Oncol,2010,28:3167-3175.
[33] LÁZÁR-MOLNÁR E,GÁCSER A,FREEMAN G J,et al.The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus histoplasma capsulatum[J].Proc Natl Acad Sci USA,2008,105:2658-2663.
[34] NAKADA T A,ODA S,MATSUDA K,et al.Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock[J].Mol Med,2008,14:257-263.
[35] PAYEN D,MATEO J,CAVAILLON J M,et al.Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis:a randomized controlled trial[J].Crit Care Med,2009,37:803-810. |
